Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid.
about
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant alleleThe influence of UGT polymorphisms as biomarkers in solid organ transplantationPopulation pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patientsEffects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritisA pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis.Herpes zoster incidence in a multicenter cohort of solid organ transplant recipientsDiabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patientsUGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipientsIntestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics.Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolitesPotential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients.Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.Pharmacogenetic influences on mycophenolate therapy.Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune diseaseThe influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights.PharmGKB summary: mycophenolic acid pathway.SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients.UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug/xenobiotic metabolizing enzymes: perspectives on molecular evolution.Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms.Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients.
P2860
Q24595480-FD1CA137-AFEB-4B97-B71C-AA54636CDAEBQ27009825-672E3ECF-87BF-472E-8ABD-10ACA6C8C87CQ28272907-4929CA37-0339-49AC-83FA-33FB03BF60B6Q28285877-AB04E767-4055-4DDB-AE1E-2A746D65454DQ34010773-A6ABE020-87B3-4BB2-859B-CEC46B9387C5Q34293248-8F16AA6B-D328-4266-B09F-417C2F832696Q34702634-E1CEC06C-0933-4263-A2A6-8B5DD8E89D6BQ34940968-E7391CE3-A3B4-4474-8C0C-0FFE6548F7C2Q34947658-0343B9CE-ADE2-4FDE-A701-9E56A8DB6C28Q34984788-8D8061E9-094B-487D-8BB8-DAF1332181A5Q35558084-5BE846EC-E89F-4FEC-8DCF-9AFB4981C097Q35578549-7DA1CEA1-AD72-4EA3-96F1-8D73F434F68FQ36400272-35CA97B7-0FED-46A1-8BBE-0C3FFA180263Q36725226-A1012EEC-2DFC-4025-99C5-C73E91AD0530Q36792638-DE5169ED-6B26-4936-AF88-F84EBF732F33Q36864810-C03A072D-5161-4021-9626-3F04CCB2ECACQ37195375-672E411B-4EA2-48CF-B662-6B30528EB336Q37221922-8577AA6C-C918-4008-9AF9-703D1FD413EAQ37415778-9F8B3596-7F39-47B1-B8FF-0178A3184C4FQ37452521-92EA7C42-AAE5-4561-B636-658E44EC4DCBQ37582505-FAE4A207-50B4-44E0-ACD3-79511DDF71AAQ37646842-41A4854D-D135-4F8B-836A-2FEEDCCD94F2Q37710509-E7DAF663-F13D-400E-9518-68BAFD40A41EQ37775981-75AC5D46-F438-43F4-A55F-2C6A8E1B7CF6Q37818144-40D2931D-0784-4225-A96F-931776C19E0EQ37857285-1B77F60C-C6B3-4DAE-A396-89063311A7C9Q38030052-B203DE77-BAA9-42F3-99D2-C022D401511DQ38063426-1341B8F7-151A-4609-A7C7-F4A9FC76A7ACQ38086603-E2F523A3-BCB5-4843-B25B-8898F7071416Q38162034-A80AF998-CA20-4AE0-A221-465ABFE8AD99Q39622403-2CF9B446-9FD4-4CB5-BA9E-4B8EC2692433Q39731863-7E442D2D-8FDC-4E0E-9B9E-E670868C15C1Q42848628-A37DB3AB-6C1D-40D0-B5AE-F243B72EA274Q42856203-5E5BB1C7-97F5-499E-A6A2-041D61721CA6Q43070323-D1F0449F-92DF-4962-A39B-858FA721A709Q46107904-77EB5669-11EB-4C05-A90F-6726046AE8FDQ46301017-50EE8314-404F-4945-86A8-94C6A0D2E5F9Q46504849-04B03863-1DB3-4A73-876C-6B98173EE4AAQ46959473-E5886B0F-B67B-4750-A827-C511B81AF4DEQ51048064-AAF127BA-1032-42F4-A91A-DCE08FA45830
P2860
Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Influence of nonsynonymous pol ...... uronides of mycophenolic acid.
@en
type
label
Influence of nonsynonymous pol ...... uronides of mycophenolic acid.
@en
prefLabel
Influence of nonsynonymous pol ...... uronides of mycophenolic acid.
@en
P2093
P356
P1476
Influence of nonsynonymous pol ...... uronides of mycophenolic acid.
@en
P2093
Jelena Tojcic
Kim Journault
Olivier Bernard
P304
P356
10.1124/DMD.106.010553
P577
2006-06-21T00:00:00Z